These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 18835771

  • 1. Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma.
    Perfumo C, Parodi S, Mazzocco K, Defferrari R, Inga A, Haupt R, Fronza G, Tonini GP.
    Eur J Cancer; 2008 Nov; 44(17):2634-9. PubMed ID: 18835771
    [Abstract] [Full Text] [Related]

  • 2. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.
    Perfumo C, Parodi S, Mazzocco K, Defferrari R, Inga A, Scarrà GB, Ghiorzo P, Haupt R, Tonini GP, Fronza G.
    Pediatr Blood Cancer; 2009 Oct; 53(4):576-83. PubMed ID: 19526525
    [Abstract] [Full Text] [Related]

  • 3. MDM2 SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma.
    Parodi S, Perfumo C, Garaventa A, Inga A, Mazzocco K, Defferrari R, Tonini GP, Fronza G, Haupt R.
    Pediatr Blood Cancer; 2010 Aug; 55(2):267-72. PubMed ID: 20232446
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP, Wong RH, Cheng YW, Chen CY, Lee H.
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [Abstract] [Full Text] [Related]

  • 7. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ, Fang C, Fan L, Zhu DX, Wang DM, Zhu HY, Zhuang Y, Miao KR, Liu P, Xu W, Li JY.
    Int J Cancer; 2012 May 01; 130(9):2054-61. PubMed ID: 21647873
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I.
    J Clin Oncol; 2008 May 10; 26(14):2252-7. PubMed ID: 18467716
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
    Han JY, Lee GK, Jang DH, Lee SY, Lee JS.
    Cancer; 2008 Aug 15; 113(4):799-807. PubMed ID: 18618574
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A, Boisselier B, Marie Y, Sanson M, El Hallani S, Crinière E, Fourtassi M, Paris S, Carpentier C, Rousseau A, Mokhtari K, Combadière C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY.
    Brain Res; 2008 Mar 10; 1198():16-20. PubMed ID: 18262501
    [Abstract] [Full Text] [Related]

  • 14. MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset.
    Hamid S, Yang YH, Peng KN, Ismail SM, Zain RB, Lim KP, Wan Mustafa WM, Abraham MT, Teo SH, Cheong SC.
    Oral Oncol; 2009 Jun 10; 45(6):496-500. PubMed ID: 18804411
    [Abstract] [Full Text] [Related]

  • 15. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger CM, Pasello M, Alberghini M, Ferrari C, Scotlandi K, Picci P, Serra M.
    Clin Cancer Res; 2009 May 15; 15(10):3550-6. PubMed ID: 19451596
    [Abstract] [Full Text] [Related]

  • 16. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
    Chua HW, Ng D, Choo S, Lum SS, Li H, Soh LY, Sabapathy K, Seow A.
    BMC Cancer; 2010 Mar 10; 10():88. PubMed ID: 20219101
    [Abstract] [Full Text] [Related]

  • 17. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.
    Kaderi MA, Mansouri M, Zainuddin N, Cahill N, Gunnarsson R, Jansson M, Kimby E, Aleskog A, Lundin J, Glimelius B, Melbye M, Juliusson G, Jurlander J, Rosenquist R.
    Leuk Res; 2010 Mar 10; 34(3):335-9. PubMed ID: 19573916
    [Abstract] [Full Text] [Related]

  • 18. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia.
    Xiong X, Wang M, Wang L, Liu J, Zhao X, Tian Z, Wang J.
    Leuk Res; 2009 Nov 10; 33(11):1454-8. PubMed ID: 19423162
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.
    Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Järvinen HJ, Mecklin JP, Atula T, Kontio R, Mäkitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA.
    J Med Genet; 2005 Sep 10; 42(9):694-8. PubMed ID: 16141004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.